Coiled Therapeutics Plc · LSE:COIL
Coiled Therapeutics — Roquefort Therapeutics — Investor Presentation (November 2024)
17 slides from Coiled Therapeutics's investor presentation, November 2024
Slide 1: Company Presentation November 2024
COMPANY PRESENTATION NOVEMBER 2024 www.roquefortplc.com
Slide 2: Disclaimer
Disclaimer Investors Resident in the UK This Presentation is only being made available to the following in the United Kingdom: persons that are "qualified investors" within the meaning of Article 2(e) of Regulation (EU) 2017/1129 as it forms part of UK law by virtue of the European Union (Withdrawal
Slide 3: Introduction
Introduction Listed on the London Stock Exchange • Standard Segment, ticker: LON: ROQ Focused on novel targets in Immunology and Oncology • STAT-6 (siRNA), Midkine (antibodies, mRNA, SSO) & MK cells 2020 Buy and build strategy Founded • Acquired Lyramid in 2021 and Oncogeni in 2022 • Re-focused R&D
Slide 4: Experienced Board & Leadership Team
Experienced Board & Leadership Team Stephen West: Executive Chairman & Founder Dr Graham Robertson: VP – Drug Discovery ▪ Fellow Chartered Accountant with over 30 years’ international financial, ▪ Associate Professor who gained his PhD in molecular virology before corporate and public company experi
Slide 5: Delivering on Our Strategy
Delivering on Our Strategy Strategy: develop first in class medicines in the high value and high growth immunology and oncology markets prior to partnering with big pharma 2021 2022 2023 2024 2 # Licensing Deals R&D Development to pre-IND 2 Listed on Acquisition Acquisition Licencing Deal London Lyr
Slide 6: Securing Licence Partners
Securing Licence Partners The Market# • Life sciences M&A spend increased to US$191B in 2023, $191B up 34% from 2022, as topline pressure and the looming patent cliff add urgency to dealmaking • Oncology remains the biggest target for dealmaking with 2023: M&A 2023 investment hitting US$65.2B • Immu
Slide 7: Focused on Three Novel Targets
Focused on Three Novel Targets STAT-6 • Patented family of siRNA targeting STAT-6 including SH2 domain • Efficacy in Oncology (in vivo) and Inflammatory & Immunology (in vitro) • STAT-6 recently validated by Sanofi Recludix pre-clinical partnership Midkine • Portfolio of patented Midkine antibody, m
Slide 8: R&D Current Status
R&D Current Status STAT-6 PROGRAMS Program Indications Safety Efficacy STAT-6 siRNA Colon cancer in vivo Completed Completed STAT-6 siRNA Colon cancer & breast cancer in combination with in vivo Completed Completed nano-particle delivery Metastasis STAT-6 siRNA THP1 model of inflammation in vitro Co
Slide 9: STAT-6 siRNA
1 STAT-6 siRNA Novel immunology and Cancer Targets • STAT-6 is an intracellular target, not druggable with conventional medicines, that is implicated in cancer development, progression, metastasis and resistance to treatment • STAT-6 recently validated by Sanofi (NASDAQ: SNY) in US$1.2B licensing de
Slide 10: Three Modalities Targeting Midkine
Three Modalities Targeting Midkine • In a validated animal model, CAB101 antibody reduces lung Humanised metastasis (p<0.5) Antibodies • CAB102 completed GLP toxicology studies and showed in vivo efficacy in osteosarcoma • Four novel patent protected SSOs Splice Switching • Lead SSO program showed >
Slide 11: Three Midkine Blocking Strategies
Three Midkine Blocking Strategies SSO mRNA Midkine secretion Exon skipping Midkine Pre-mRNA Truncated X X Midkine protein X X Antibodies X X X C Truncated X Midkine V protein C Tumour-Associated X X V Macrophage M2 Macrophage Arg1 X Phenotype IL-10 EREG November 2024 Page 11
Slide 12: Midkine Antibodies
2 Midkine Antibodies Midkine antibody family shows in vivo efficacy in validated animal models • Midkine family of antibodies includes four novel patent protected antibodies (IP9,10,13 & 14) • In a validated animal model, CAB101 antibody reduces lung metastasis (p<0.5) • CAB102 completed GLP toxicol
Slide 13: Midkine RNA Oligonucleotides
3 Midkine RNA Oligonucleotides in vivo study demonstrated reduced cancer Midkine • Midkine (MDK) family of oligonucleotides includes 4 novel patent protected RNA sequences • Lead SSO program showed >90% efficacy at the mRNA level, reducing functional Midkine • Truncated MDK shows efficacy in validat
Slide 14: Midkine mRNA
4 Midkine mRNA in vivo study demonstrated reduced cancer Midkine • mRNA family includes two novel patent protected mRNA sequences • mRNA significantly reduces MDK mRNA levels in in vitro breast and liver cancer models • Patent protected with composition of matter IP • Highly complementary approach t
Slide 15: MK Cellular Therapeutic
5 MK Cellular Therapeutic Novel, human cell engineered to kill cancer • Novel anti-cancer cell type invented by Nobel Laureate, Prof. Sir Martin Evans which kill cancer directly and also activate the immune system’s Natural Killer (NK) cells and to kill cancer as a next generation immunotherapy • Tr
Slide 16: Summary
Summary London listed biotech company focused on creating next generation medicines 1 for Immunology and Oncology Delivered positive R&D results for all 5 pre-clinical programs + Randox 2 commercial licence + PDC transaction# Partnered with leading academic cancer research centres which complements
Slide 17: www.roquefortplc.com
www.roquefortplc.com
Roquefort Therapeutics — Investor Presentation (November 2024) on 6ix